{"filing":{"accession_number":"0001213900-26-079420","cik":"0002023311","ticker":"AAPG","company_name":"ASCENTAGE PHARMA GROUP INTERNATIONAL","form":"6-K","filing_date":"2026-07-20","report_date":null,"primary_document":"ea0298534-6k_ascentage.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2023311/000121390026079420/ea0298534-6k_ascentage.htm"},"events":[{"id":18703,"run_id":16822,"accession_number":"0001213900-26-079420","anchor_item_number":"EX-99.1","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The exhibit discloses a proposed at-the-market (ATM) offering program of up to $200 million in American Depositary Shares (ADSs) representing ordinary shares, filed with the SEC on Form F-3. This is an unregistered equity issuance that will dilute existing shareholders. The announcement explicitly states the Company expects the underlying ordinary shares to represent up to 20% of total issued shares, and the offering is subject to Hong Kong listing rule waivers. This is a material capital-raising event that would affect investor assessment of ownership dilution and the Company's financing strategy.","company_name":"ASCENTAGE PHARMA GROUP INTERNATIONAL","ticker":"AAPG","filing_date":"2026-07-20","form":"6-K","submitted_at":null,"items":[{"id":17592,"accession_number":"0001213900-26-079420","item_number":"EX-99.1","item_title":"ea029853401ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The exhibit discloses a proposed at-the-market (ATM) offering program of up to $200 million in American Depositary Shares (ADSs) representing ordinary shares, filed with the SEC on Form F-3. This is an unregistered equity issuance that will dilute existing shareholders. The announcement explicitly states the Company expects the underlying ordinary shares to represent up to 20% of total issued shares, and the offering is subject to Hong Kong listing rule waivers. This is a material capital-raising event that would affect investor assessment of ownership dilution and the Company's financing strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-20T13:17:15.839684+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17592,"accession_number":"0001213900-26-079420","item_number":"EX-99.1","item_title":"ea029853401ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The exhibit discloses a proposed at-the-market (ATM) offering program of up to $200 million in American Depositary Shares (ADSs) representing ordinary shares, filed with the SEC on Form F-3. This is an unregistered equity issuance that will dilute existing shareholders. The announcement explicitly states the Company expects the underlying ordinary shares to represent up to 20% of total issued shares, and the offering is subject to Hong Kong listing rule waivers. This is a material capital-raising event that would affect investor assessment of ownership dilution and the Company's financing strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-20T13:17:15.839684+00:00","company_name":"ASCENTAGE PHARMA GROUP INTERNATIONAL","ticker":"AAPG","filing_date":"2026-07-20"}]}